Journal
MOLECULAR CANCER
Volume 18, Issue 1, Pages -Publisher
BMC
DOI: 10.1186/s12943-019-1119-7
Keywords
RNA m(6)A methylation; Wnt; beta-catenin pathway; CTNNB1; Hepatoblastoma; METTL3
Categories
Funding
- Program of Shanghai Academic/Technology Research Leader [18XD1402600]
- Municipal Human Resources Development Program for Outstanding Leaders in Medical Disciplines in Shanghai [2017BR036]
- Shanghai Municipal Education Commission -Gaofeng Clinical Medicine Grant Support [20171926]
- Science and Technology Development. Fund of Pudong New Area of Shanghai [PKJ2017-Y03]
- National Natural Science Foundation of China [81702741, 81572330, 81871727, 81472624, 81772941]
- National Natural Science Foundation [81930066]
- Shanghai anti-cancer association eagle plan [SACA-CY1B05]
- Shanghai municipal health and family planning commission [20174Y0228]
- Natural Science Foundation of Science and Technology Commission of Shanghai [17ZR1421700]
Ask authors/readers for more resources
Background N-6-Methyladenosine (m(6)A) modification has been implicated in many biological processes. It is important for the regulation of messenger RNA (mRNA) stability, splicing, and translation. However, its role in cancer has not been studied in detail. Here we investigated the biological role and underlying mechanism of m(6)A modification in hepatoblastoma (HB). Methods We used Reverse transcription quantitative real-time PCR (RT-qPCR) and Western blotting to determine the expression of m(6)A related factors. And we clarified the effects of these factors on HB cells using cell proliferation assay, colony formation, apoptotic assay. Then we investigated of methyltransferase-like 13 (METTL3) and its correlation with clinicopathological features and used xenograft experiment to check METTL3 effect in vivo. m(6)A-Seq was used to profiled m(6)A transcriptome-wide in hepatoblastoma tumor tissue and normal tissue. Finally, methylated RNA immunoprecipitation (MeRIP) assay, RNA remaining assay to perform the regulator mechanism of MEETL3 on the target CTNNB1 in HB. Results In this research, we discovered that m(6)A modifications are increased in hepatoblastoma, and METTL3 is the main factor involved with aberrant m(6)A modification. We also profiled m(6)A across the whole transcriptome in hepatoblastoma tumor tissues and normal tissues. Our findings suggest that m(6)A is highly expressed in hepatoblastoma tumors. Also, m(6)A is enriched not only around the stop codon, but also around the coding sequence (CDS) region. Gene ontology analysis indicates that m(6)A mRNA methylation contributes significantly to regulate the Wnt/beta-catenin pathway. Reduced m(6)A methylation can lead to a decrease in expression and stability of the CTNNB1. Conclusion Overall our findings suggest enhanced m(6)A mRNA methylation as an oncogenic mechanism in hepatoblastoma, METTL3 is significantly up-regulated in HB and promotes HB development. And identify CTNNB1 as a regulator of METTL3 guided m(6)A modification in HB.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available